维普期刊资源整合服务平台（V6.5）

23篇 您的检索式：作者名="Bomalaski JS"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Pegylated Arginine Deiminase (ADI-SS PEG20,O00 row)Inhibits Human Melanomasand Hepatocellular Carcinomasin Vitro and in Vivo显示文摘	ENSOR CM HOLTSBERG FW BOMALASKI JS	2002	Cancer research2002，62，：	1
2	Pegylated arginine deminase (ADI-SS PEG20,000mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo 显示文摘	Ensor CM Holtsberg FW Bomalaski JS	2002	Cancer Res2002，62，19：	1
3	Uricase formulated with polyethylene glycol(Uricase-PEG 20):biochemical rationale and preclinical studies显示文摘	Bomalaski JS Holtsberg FW Ensor CM	2002	J Rheumatol2002，29，9：	1
4	Serum uric acid-lowering therapies:where are we heading in management of hyperuricemia and the potential role of uricase显示文摘	Bomalaski JS Clark MA		0，，03：	1
5	Serum uric acid lowering the rapies: where are we heading in management of hyperuricemia and the potential role of uricase 显示文摘	Bomalaski JS Clark MA	2004	Curr Rheumatol Rep2004，6，3：	1
6	Serum uric acid-lowing therapies,where are we heading in management of hyperuricemia and the potential role of uricase 显示文摘	Bomalaski JS Clark MA	2004	Curr Rheumatol Rep2004，6，3：	1
7	Serum uric acid-lowering therapies: Where are we heading in management of hyperuricemia and the potential role of uricase显示文摘	Bomalaski JS Clark MA	2004	Curt Rheumatol Rep2004，6，3：	1
8	Serum uric acid-lowering therapies:whereare we leading in management of hyperuricemia and the potential roleof uricase显示文摘	Bomalaski JS Clark MA	2004	Curr Rheumatol Rep2004，6，3：	1
9	Formulation of arginine deiminase with polyethylene glycol(peg):effects of different linkers and molecular weight of PKG on the pharmacokinetics,pharma-codynamics and immunogenicity of this enzyme显示文摘	Holtsberg FW Ensor CM Bomalaski JS	2002	J Controlled Release2002，2380，13：	1
10	Rheumatoid arthritis synovial fluid phospholipase A2 activating protein(PLAP) stimulates human neutrophil degranulation and superoxide ion production显示文摘	BOMALASKI JS BAKER D RESURRECCION NV	1989	Agents Actions1989，27，：	1
11	Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies显示文摘	Bomalaski JS Holtsberg FW Ensor CM Clark MA	2002	J Rheumatol2002，29，9：	1
12	Serum uric acid-lowering therapies:where are we heading in management of hyperuricemia and the potential role of uricase显示文摘	Bomalaski JS Clark MA	2004	Curr Rheumatol Rep2004，6，3：	1
13	Serum uric acid-lowering therapies where are we heading in management of hyperuricemia and the potential role of uricase 显示文摘	Bomalaski JS Clark MA	2004	Curr Rheumatol Rep2004，6，3：	1
14	Serum uric acid lowering therapies:where are we heading in management of hyperuricemia and the potential role of uricase显示文摘	Bomalaski JS Clark MA	2004	Curr Rheum atol Rep2004，6，3：	1
15	Serum uric acid lowering therapies:where are we heading in management of hyperuricemia and the potential role of uricase显示文摘	Bomalaski JS Clark MA	2004	Curr Rheumatol Rep2004，6，3：	1
16	Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo显示文摘	Ensor CM Holtsberg FW Bomalaski JS	2002	Cancer Res2002，62，19：	1
17	Serum uric acid-lowering therapies: where are we leading in management of hyper- uricemia and the potential role of uricase显示文摘	Bomalaski JS Clark MA	2004	Curr Rheumatol Rep2004，6，3：	1
18	Serum uric acid lowering therapies: Where are we heading in management of hyperuricemia and the potential role of uriease 显示文摘	Bomalaski JS Clark MA	2004	Curr Rheum atoll Rep2004，6，3：	1
19	Pegylated arginine deiminase (ADI- SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo显示文摘	Ensor CM Holtsberg FW Bomalaski JS	2002	Cancer Res2002，62，：	1
20	Serum uric acid-lowering therapies: where are we leading in management of hyperuricemia and the potential role of uricase 显示文摘	Bomalaski JS Clark MA	2004	Curt Rheumatol Rep2004，6，3：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示